Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Atopic Dermatitis Eczema · Plaque Psoriasis · ARQT

Arcutis Biotherapeutics

Arcutis Biotherapeutics clinical programs — 27 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
2945 Townsgate Rd, Westlake Village, California 91361, US HQ
2016 Founded
427 Employees
Public company Type
ARQT · NYSE Ticker
Company details
Status
Public
HQ
2945 Townsgate Rd, Westlake Village, California 91361, US
Founded
2016
Employees
427
Programs
27
Drugs
3
Patents
30
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Arcutis Biotherapeutics projects

27 ClinicalTrials.gov programs sponsored by Arcutis Biotherapeutics.

Arcutis Biotherapeutics has 27 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

27 programs

Clinical programs

  1. ARQ-151 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  2. ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  3. Roflumilast 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  4. Roflumilast Cream

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  5. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  6. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  7. Roflumilast Foam

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial

  8. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial

  9. Topical roflumilast

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  10. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  11. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials

  12. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial

  13. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Vitiligo

    phase 2 small molecule terminated

    1 trial

  15. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Chronic Hand Eczema

    phase 2 small molecule completed

    1 trial

  16. Roflumilast

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  17. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  18. Roflumilast Cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  19. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. Roflumilast foam 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  21. Roflumilast topical 0.3% foam

    Arcutis Biotherapeutics

    Non-segmental Vitiligo

    phase 2 small molecule active

    1 trial

  22. Topical roflumilast 0.3% foam

    Arcutis Biotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  23. ARQ-151 cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 1 small molecule completed

    1 trial

  24. ARQ-151- cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial

  25. ARQ-154 Foam 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 1 small molecule completed

    1 trial

  26. ARQ-234

    Arcutis Biotherapeutics

    Atopic Dermatitis (AD)

    phase 1 mab active

    1 trial

  27. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    ITCH

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Arcutis Biotherapeutics have?

27 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.